Diagnology files to market herpes test in US
This article was originally published in Clinica
Executive Summary
Diagnology has filed for clearance to market its rapid point-of-care test for the herpes simplex virus, HSV 2, in the US. The POCkit test, an immunoassay, identifies patients infected with genital herpes by detecting HSV 2 specific antibodies in their blood, regardless of whether symptoms are present or not. The test, which can produce results in under 10 minutes, is already available in Europe, said the Belfast-based company.